Fibroid Ablation Study
The primary objective of this study is to establish the effectiveness and confirm the safety of the VizAblate System in ablating symptomatic uterine fibroids.
Leiomyoma|Uterine Fibroids|Menorrhagia
DEVICE: VizAblate System
Mean percentage change in target fibroid perfused volume, 3 months
Number of adverse events, Procedure safety will be assessed by recording all adverse events that occur on the day of the procedure. Longer-term safety will be assessed by recording at each follow-up visit any untoward medical occurrence since baseline. Each adverse event will be assessed for severity and relationship to study device., procedure through 12 mo|Percentage reduction in Menstrual Pictogram score, baseline through 12 months|Percentage reduction in the Symptom Severity Subscale (SSS) of the Uterine Fibroid Symptom and Quality of Life (UFS-QOL) questionnaire, baseline through 12 months|Rate of surgical reintervention for menorrhagia, through 12 months|Return to normal daily activity, 2 weeks or until returned to normal activity
Subject satisfaction, 3 month, 6 month, 12 months|Anesthesia regimen, Day of procedure|System ease of use, End of study|Subject pain and tolerance of procedure, Day of procedure|HRQL sub scale of Uterine Fibroid Symptom Quality of Life (UFS-QOL) questionnaire, 3 month, 6 month, 12 months|EuroQOL EQ-5D, 3 month, 6 month, 12 month|Length of Stay, Day of procedure|Nonsurgical reintervention for menorrhagia, 30 day, 3 month, 6 month, 12 month
The primary objective of this study is to establish the effectiveness and confirm the safety of the VizAblate System in ablating symptomatic uterine fibroids.